The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations]
Background: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharma...
Main Authors: | Rana M. ElDash, Mohamed A. Raslan, Sara M. Shaheen, Nagwa Ali Sabri |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2021-04-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/10-321/v1 |
Similar Items
-
Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers
by: Mohammed Murtadha, et al.
Published: (2021-06-01) -
Pharmacokinetic-pharmacodynamic relationship of anesthetic drugs: from modeling to clinical use [version 1; referees: 4 approved]
by: Valerie Billard
Published: (2015-11-01) -
Automated Wormscan [version 1; referees: 2 approved, 1 approved with reservations]
by: Timothy Puckering, et al.
Published: (2017-02-01) -
The future of metabolomics in ELIXIR [version 1; referees: 2 approved, 1 approved with reservations]
by: Merlijn van Rijswijk, et al.
Published: (2017-09-01) -
FAIRness in scientific publishing [version 1; referees: 1 approved, 2 approved with reservations]
by: Philippa C. Matthews
Published: (2016-12-01)